

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2368658/jaffer-a-ajani-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

444 papers	27,422 citations	79 h-index	158 g-index
512 ext. papers	33,513 ext. citations	6.3 avg, IF	6.73 L-index

#	Paper	IF	Citations
444	Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. <i>New England Journal of Medicine</i> , 2001 , 345, 725-30	59.2	2668
443	Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4991-7	2.2	1502
442	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 1224-35	21.7	1457
441	Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. <i>New England Journal of Medicine</i> , 1998 , 339, 1979-84	59.2	1085
440	Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 1914-21	27.4	609
439	Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2327-33	2.2	563
438	Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1286-1312	7.3	522
437	Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1547-53	2.2	422
436	Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3719-25	2.2	407
435	Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4344-51	2.2	359
434	Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3935-43	2.2	358
433	Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. <i>Cancer</i> , 2005 , 103, 1347-55	6.4	338
432	Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 531-46	7.3	334
431	Gastric cancer-molecular and clinical dimensions. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 643-55	19.4	307
430	Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. <i>Annals of Thoracic Surgery</i> , 2004 , 78, 1152-60; discussion 1152-60	2.7	274
429	Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3953-8	2.2	272
428	The crosstalk of mTOR/S6K1 and Hedgehog pathways. <i>Cancer Cell</i> , 2012 , 21, 374-87	24.3	270

427	Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 855-883	7.3	267
426	Esophageal and esophagogastric junction cancers, version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 194-227	7.3	257
425	Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. <i>Lancet Oncology, The</i> , 2017 , 18, 640-653	21.7	254
424	Gastric adenocarcinoma. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17036	51.1	251
423	Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. <i>Gastroenterology</i> , 2011 , 141, 476-85, 485.e1-11	13.3	244
422	Gene expression signature-based prognostic risk score in gastric cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 1850-7	12.9	232
421	ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. <i>Nature Medicine</i> , 2018 , 24, 556-562	50.5	227
420	The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. <i>Cell Research</i> , 2020 , 30, 146-162	24.7	225
419	2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. <i>Cancer</i> , 2004 , 101, 1776-85	6.4	217
418	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2021 , 398, 27-40	40	216
417	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. <i>Clinical Cancer Research</i> , 2017 , 23, 4441-4449	12.9	213
416	Cancer stem cells: the promise and the potential. <i>Seminars in Oncology</i> , 2015 , 42 Suppl 1, S3-17	5.5	208
415	Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3205-9	2.2	208
414	Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5660-7	2.2	189
413	Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. <i>Annals of Surgery</i> , 1999 , 229, 303-8	7.8	189
412	Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 2350-62	6.1	188
411	Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, 1078-85	4	179
410	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017 , 35, 446-464	2.2	176

409	Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. <i>Cancer</i> , 2007 , 109, 658-67	6.4	169
408	Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. <i>Cancer Research</i> , 2014 , 74, 4170-82	10.1	167
407	Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. <i>New England Journal of Medicine</i> , 2021 , 384, 1191-1203	59.2	167
406	Evolving chemotherapy for advanced gastric cancer. <i>Oncologist</i> , 2005 , 10 Suppl 3, 49-58	5.7	163
405	The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 2580-90	12.9	155
404	Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3789-98	2.2	153
403	Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6957-65	2.2	152
402	Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. <i>Cancer</i> , 1991 , 68, 1501-6	6.4	147
401	Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3210-6	2.2	145
400	Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2012 , 75, 242-53	5.2	142
399	Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. <i>Journal of Clinical Oncology</i> , 2006 , 24, 259-67	2.2	142
398	CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. <i>Cancer</i> , 2002 , 94, 641-6	6.4	142
397	Esophageal and esophagogastric junction cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 830-87	7.3	139
396	Laparoscopic staging for gastric cancer. <i>Surgery</i> , 1996 , 119, 611-4	3.6	138
395	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. <i>Gut</i> , 2015 , 64, 1721-31	19.2	137
394	Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. <i>Cancer</i> , 2012 , 118, 2632-40	6.4	134
393	Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. <i>Clinical Cancer Research</i> , 2005 , 11, 656-63	12.9	133
392	Association of activated transcription factor nuclear factor kappaB with chemoradiation resistance and poor outcome in esophageal carcinoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 748-54	2.2	124

391	Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). <i>Annals of Surgery</i> , 2005 , 241, 810-7; discussion 817-20	7.8	122
390	Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. <i>Clinical Cancer Research</i> , 2006 , 12, 6565-72	12.9	121
389	Gastric cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8, 378-409	7.3	119
388	Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. <i>Nature Communications</i> , 2018 , 9, 1777	17.4	116
387	Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. <i>Gut</i> , 2013 , 62, 1100-11	19.2	114
386	A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. <i>Cancer</i> , 2001 , 92, 279-86	6.4	108
385	Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. <i>Cancer</i> , 2005 , 104, 1349-55	6.4	103
384	Medical management of gastric cancer: a 2017 update. <i>Cancer Medicine</i> , 2018 , 7, 123-133	4.8	100
383	Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 81, 1336-42	4	99
382	Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4551-6	2.2	98
381	Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. <i>Cancer Investigation</i> , 1999 , 17, 474-8	2.1	97
380	Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. <i>Cancer</i> , 2005 , 104, 2365-72	6.4	94
379	Small cell carcinoma of the esophagus. <i>Cancer</i> , 2000 , 88, 262-267	6.4	93
378	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5671-5678	12.9	91
377	A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. <i>Annals of Surgical Oncology</i> , 2001 , 8, 519-24	3.1	91
376	Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. <i>Cancer</i> , 2007 , 109, 125-34	6.4	90
375	Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 87, 638-45	4	89
374	Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. <i>American Journal of Surgical Pathology</i> , 2007 , 31, 58-64	6.7	89

373	Predictors of postoperative complications after trimodality therapy for esophageal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 885-91	4	86
372	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- β Superfamily. <i>Cell Systems</i> , 2018 , 7, 422-437.e7	10.6	85
371	Proton beam therapy and concurrent chemotherapy for esophageal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, e345-51	4	84
370	Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 663-7	2.2	84
369	H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8- β Catenin Signaling in Colorectal Cancer. <i>EBioMedicine</i> , 2016 , 13, 113-124	8.8	84
368	Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2403-11	2.2	83
367	Gastric cancer and metastasis to the brain. <i>Annals of Surgical Oncology</i> , 1999 , 6, 771-6	3.1	81
366	The role of microRNAs in cancers of the upper gastrointestinal tract. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013 , 10, 109-18	24.2	79
365	Carcinoid tumors: imaging procedures and interventional radiology. <i>World Journal of Surgery</i> , 1996 , 20, 147-56	3.3	78
364	MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. <i>Cancer Prevention Research</i> , 2013 , 6, 196-205	3.2	77
363	Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. <i>International Journal of Oncology</i> , 2014 , 45, 567-74	4.4	76
362	Metformin use and improved response to therapy in esophageal adenocarcinoma. <i>Acta Oncologica</i> , 2013 , 52, 1002-9	3.2	76
361	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nature Communications</i> , 2017 , 8, 1050	17.4	75
360	A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 443-454	6.1	75
359	Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. <i>Gut</i> , 2020 , 69, 748-763	19.2	74
358	Esophageal cancer dose escalation using a simultaneous integrated boost technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 468-74	4	74
357	Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2016 , 23, 4332-4337	3.1	72
356	Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. <i>Cancer</i> , 1993 , 71, 3690-6	6.4	72

355	Clinical benefit of palliative radiation therapy in advanced gastric cancer. <i>Acta Oncologica</i> , 2008 , 47, 421-73.2	7.2	71
354	Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1569-1579	2.2	70
353	Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. <i>Radiotherapy and Oncology</i> , 2018 , 128, 154-160	5.3	68
352	Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. <i>Clinical Cancer Research</i> , 2005 , 11, 2229-36	12.9	66
351	US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1116-21	2.2	65
350	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. <i>Archives of Pathology and Laboratory Medicine</i> , 2016 , 140, 1345-1363	5	64
349	A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 1967-72	4	64
348	Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2017 , 24, 3338-3344	3.1	63
347	Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3400-5	2.2	63
346	Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. <i>Cancer</i> , 2011 , 117, 4823-33	6.4	63
345	An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. <i>Cancer</i> , 2006 , 106, 1908-16	6.4	62
344	Islet cell carcinoma of the pancreas. A study of 98 patients. <i>Cancer</i> , 1990 , 65, 354-7	6.4	62
343	Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. <i>Gastroenterology</i> , 2015 , 149, 1599-606	13.3	61
342	Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ. <i>Hepatology</i> , 2016 , 64, 1757-1772	11.2	61
341	Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. <i>Cancer</i> , 2017 , 123, 4106-4113	6.4	61
340	Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2012 , 94, 1126-32; discussion 1132-3	2.7	61
339	Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. <i>Cancer Prevention Research</i> , 2009 , 2, 459-65	3.2	61
338	Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. <i>Cancer</i> , 2004 , 100, 2347-54	6.4	61

337	Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3094-103	2.2	58
336	Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. <i>Cancer Treatment Reviews</i> , 2018 , 66, 104-113	14.4	57
335	A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. <i>Investigational New Drugs</i> , 2006 , 24, 353-7	4.3	56
334	Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. <i>Cancer</i> , 2008 , 113, 945-55	6.4	55
333	Adjuvant therapy for gastric carcinoma patients in the past 15 years. <i>Cancer</i> , 1999 , 86, 1657-1668	6.4	55
332	Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. <i>Cancer Research</i> , 2008 , 68, 2632-40	10.1	54
331	Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. <i>Cancer</i> , 2007 , 109, 33-40	6.4	54
330	Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling. <i>Gastroenterology</i> , 2018 , 154, 1524-1537.e6	13.3	53
329	Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 667-676	4	53
328	Loss of TGF- β adaptor β SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. <i>Cancer Research</i> , 2013 , 73, 2159-69	10.1	53
327	Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. <i>Cancer</i> , 2006 , 107, 221-31	6.4	53
326	Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4306-10	2.2	52
325	Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. <i>Gastric Cancer</i> , 2018 , 21, 31-40	7.6	51
324	The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. <i>Cancer</i> , 2009 , 115, 5184-92	6.4	50
323	Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 1098-105	4	48
322	Preoperative Chemo-Radiation-Induced Ulceration in Patients with Esophageal Cancer: A Confounding Factor in Tumor Response Assessment in Integrated Computed Tomographic-Positron Emission Tomographic Imaging. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 478-486	8.9	46
321	Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 368-374	8.9	45
320	Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. <i>Cancer</i> , 2010 , 116, 2511-8	6.4	45

319	Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. <i>Annals of Surgical Oncology</i> , 2017 , 24, 2679-2687	3.1	44
318	LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. <i>Molecular Cancer</i> , 2019 , 18, 141	42.1	44
317	Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. <i>British Journal of Cancer</i> , 2016 , 115, 974-982	8.7	44
316	Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 375-382	8.9	43
315	A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. <i>Cancer</i> , 2014 , 120, 3635-41	6.4	42
314	Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. <i>Annals of Surgical Oncology</i> , 2007 , 14, 2010-7	3.1	42
313	Standard chemotherapy for gastric carcinoma: is it a myth?. <i>Journal of Clinical Oncology</i> , 2000 , 18, 4001-3	3.2	42
312	A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5-5	2.2	42
311	Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. <i>Annals of Thoracic Surgery</i> , 2014 , 98, 1064-71	2.7	41
310	The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. <i>BMC Gastroenterology</i> , 2009 , 9, 77	3	41
309	Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. <i>Annals of Thoracic Surgery</i> , 2010 , 90, 892-8; discussion 898-9	2.7	41
308	Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1202-6	8.9	40
307	Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. <i>Gut</i> , 2020 , 69, 18-31	19.2	39
306	Targeted literature review of the global burden of gastric cancer. <i>Ecancermedicalscience</i> , 2018 , 12, 883	2.7	39
305	Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. <i>Gastric Cancer</i> , 2018 , 21, 74-83	7.6	37
304	Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022 , 20, 167-192	7.3	37
303	Multidisciplinary management of gastric cancer. <i>Current Opinion in Gastroenterology</i> , 2010 , 26, 640-6	3	36
302	Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. <i>JAMA Oncology</i> , 2019 , 5, 1597-1604	13.4	35

301	Extracellular Vesicles from Cancer-Associated Fibroblasts Containing Annexin A6 Induces FAK-YAP Activation by Stabilizing β 1 Integrin, Enhancing Drug Resistance. <i>Cancer Research</i> , 2020 , 80, 3222-3235	10.1	35
300	18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. <i>European Journal of Cancer</i> , 2015 , 51, 2545-52	7.5	34
299	The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. <i>Oncology</i> , 2016 , 90, 239-47	3.6	34
298	Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, 581-6	4	34
297	Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. <i>Cancer</i> , 2006 , 107, 1475-82	6.4	34
296	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. <i>Gastroenterology</i> , 2020 , 159, 2146-2162.e33	13.3	34
295	YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 2264-2277	12.9	34
294	Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2020 , 23, 95-104	7.6	34
293	Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. <i>Cancer</i> , 2018 , 124, 998-1007	6.4	33
292	The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. <i>Gastric Cancer</i> , 2018 , 21, 1-9	7.6	32
291	Genetic and intermediate phenotypic susceptibility markers of gastric cancer in Hispanic Americans: a case-control study. <i>Cancer</i> , 2014 , 120, 3040-8	6.4	32
290	Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. <i>Oncology</i> , 2013 , 85, 95-9	3.6	31
289	Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. <i>Oncology</i> , 2012 , 83, 300-4	3.6	31
288	Medical management of gastric cancer: a 2014 update. <i>World Journal of Gastroenterology</i> , 2014 , 20, 1363-647	3.647	31
287	Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. <i>Cancer</i> , 1995 , 75, 451-6	6.4	30
286	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.. <i>New England Journal of Medicine</i> , 2022 , 386, 449-462	59.2	30
285	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. <i>American Journal of Clinical Pathology</i> , 2016 , 146, 647-669	1.9	30
284	Drug resistance and Cancer stem cells. <i>Cell Communication and Signaling</i> , 2021 , 19, 19	7.5	30

283	Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. <i>Nature Medicine</i> , 2021 , 27, 141-151	50.5	30
282	Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 149	22.4	28
281	Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. <i>Journal of the American College of Surgeons</i> , 2015 , 221, 83-90	4.4	28
280	Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 2215-2222	6.1	27
279	Ramucirumab: a novel antiangiogenic agent. <i>Future Oncology</i> , 2013 , 9, 789-95	3.6	27
278	Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. <i>Cancer</i> , 2009 , 115, 624-30	6.4	27
277	A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastro-esophageal junction (G/GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4011-4011	2.2	27
276	Targeting Angiogenesis in Colorectal Carcinoma. <i>Drugs</i> , 2019 , 79, 63-74	12.1	27
275	Is endoscopic ultrasound examination necessary in the management of esophageal cancer?. <i>World Journal of Gastroenterology</i> , 2017 , 23, 751-762	5.6	26
274	Molecular biomarkers in gastric cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, e19-29	7.3	26
273	Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. <i>Annals of Thoracic Surgery</i> , 2010 , 90, 884-90; discussion 890-1	2.7	26
272	ERCC1 and ERCC2 variants predict survival in gastric cancer patients. <i>PLoS ONE</i> , 2013 , 8, e71994	3.7	26
271	Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. <i>Annals of Surgical Oncology</i> , 2019 , 26, 1394-1400	3.1	25
270	Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. <i>Annals of Surgical Oncology</i> , 2014 , 21, 306-14	3.1	25
269	Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1730-1737.e9	6.9	25
268	Current strategies in the management of locoregional and metastatic gastric carcinoma. <i>Cancer</i> , 1991 , 67, 260-5	6.4	25
267	Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. <i>Annals of Surgical Oncology</i> , 2016 , 23, 156-62	3.1	24
266	Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2019 , 22, 803-816	7.6	24

265	Global chemotherapy development for gastric cancer. <i>Gastric Cancer</i> , 2017 , 20, 92-101	7.6	24
264	Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. <i>Journal of Surgical Oncology</i> , 2015 , 112, 883-7	2.8	24
263	ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. <i>Oncotarget</i> , 2015 , 6, 25883-96	3.3	24
262	Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. <i>Journal of Clinical Investigation</i> , 2020 , 130, 5951-5966	15.9	24
261	Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. <i>Journal of Surgical Oncology</i> , 2016 , 113, 29-35	2.8	22
260	Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. <i>American Journal of Cancer Research</i> , 2017 , 7, 473-483	4.4	22
259	Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. <i>Annals of Surgical Oncology</i> , 2018 , 25, 2012-2017	3.1	21
258	Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2017 , 24, 960-965	3.1	21
257	Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. <i>Oncology</i> , 2013 , 85, 204-7	3.6	21
256	The role of hedgehog signaling in gastric cancer: molecular mechanisms, clinical potential, and perspective. <i>Cell Communication and Signaling</i> , 2019 , 17, 157	7.5	21
255	YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. <i>Gut</i> , 2021 , 70, 55-66	19.2	21
254	Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. <i>Journal of Surgical Oncology</i> , 2015 , 111, 875-81	2.8	20
253	Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric cancer. <i>Molecular Carcinogenesis</i> , 2015 , 54, 880-8	5	20
252	Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. <i>Gastric Cancer</i> , 2018 , 21, 1004-1013	7.6	20
251	Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. <i>British Journal of Cancer</i> , 2017 , 117, 648-655	8.7	20
250	Preoperative Chemo-Radiation-Induced Ulceration in Patients with Esophageal Cancer: A Confounding Factor in Tumor Response Assessment in Integrated Computed Tomographic-Positron Emission Tomographic Imaging. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 478-486	8.9	20
249	Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. <i>Investigational New Drugs</i> , 2001 , 19, 341-3	4.3	20
248	The human tumor stem cell assay revisited. <i>International Journal of Cell Cloning</i> , 1985 , 3, 116-28		20

247	Liquid biopsies in gastrointestinal malignancies: when is the big day?. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 19-38	3.5	20
246	Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. <i>Molecular Carcinogenesis</i> , 2015 , 54, 449-58	5	19
245	Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. <i>Cancer</i> , 2007 , 110, 989-95	6.4	19
244	It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 475-477	2.2	18
243	Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. <i>Annals of Surgery</i> , 2018 , 268, 289-295	7.8	18
242	The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. <i>Oncology</i> , 2010 , 78, 316-22	3.6	18
241	Predictors of staging accuracy, pathologic nodal involvement, and overall survival for cT2N0 carcinoma of the esophagus. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019 , 157, 1264-1272.e6	1.5	18
240	Serum miR-331-3p predicts tumor recurrence in esophageal adenocarcinoma. <i>Scientific Reports</i> , 2018 , 8, 14006	4.9	18
239	Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. <i>Oncology</i> , 2002 , 16, 16-8	1.8	18
238	Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy. <i>Annals of Surgical Oncology</i> , 2018 , 25, 2720-2730	3.1	17
237	Recent developments in oral chemotherapy options for gastric carcinoma. <i>Drugs</i> , 1999 , 58 Suppl 3, 85-90	2.1	17
236	Recent advances in the management of gastric adenocarcinoma patients. <i>F1000Research</i> , 2018 , 7,	3.6	17
235	Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 6228-6235	12.9	17
234	Advanced gastric adenocarcinoma: optimizing therapy options. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 263-271	3.8	16
233	Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. <i>Annals of Surgical Oncology</i> , 2019 , 26, 3602-3610	3.1	16
232	Substituting ornithine for arginine in total parenteral nutrition eliminates enhanced tumor growth. <i>Journal of Surgical Oncology</i> , 1992 , 50, 161-7	2.8	16
231	Epstein-Barr virus-associated gastric cancer: disease that requires special approach. <i>Gastric Cancer</i> , 2020 , 23, 951-960	7.6	15
230	Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, e231-9	4	15

229	Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1627-31	4	15
228	Molecular mechanisms in cancer: what should clinicians know?. <i>Seminars in Oncology</i> , 2005 , 32, 2-4	5.5	15
227	Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. <i>Cancer</i> , 1993 , 71, 1214-8	6.4	15
226	Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 121-121	2.2	15
225	A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015 , 6, 45-52	2.8	15
224	Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). <i>Journal of Gastrointestinal Cancer</i> , 2015 , 46, 109-17	1.6	14
223	Immunotherapy for esophageal cancer: a 2019 update. <i>Immunotherapy</i> , 2020 , 12, 203-218	3.8	14
222	Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 1009-1017	2.8	14
221	Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 660-666	4	14
220	Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. <i>Oncology</i> , 2014 , 86, 336-9	3.6	14
219	Gastroesophageal junction adenocarcinoma. <i>Current Treatment Options in Oncology</i> , 2000 , 1, 387-98	5.4	14
218	Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. <i>Annals of Thoracic Surgery</i> , 2016 , 101, 1075-80; Discussion 1080-1	2.7	14
217	ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1663-1670	12.9	14
216	Docetaxel for gastric and esophageal carcinomas. <i>Oncology</i> , 2002 , 16, 89-96	1.8	14
215	Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?. <i>Annals of Surgical Oncology</i> , 2016 , 23, 626-32	3.1	13
214	Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1139-44	7.3	13
213	Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2013 , 17, 1359-69	3.3	13
212	Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. <i>Cancer</i> , 2010 , 116, 1656-63	6.4	13

211	Molecular epidemiology of gastric cancer: current status and future prospects. <i>Gastrointestinal Cancer Research: GCR</i> , 2007 , 1, 12-9		13
210	SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. <i>Cancers</i> , 2019 , 11,	6.6	13
209	Endoscopic management of esophageal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2019 , 11, 830-841	3.4	13
208	The ypT category does not impact overall survival in node negative gastric cancer. <i>Journal of Surgical Oncology</i> , 2018 , 117, 1721-1728	2.8	13
207	Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. <i>Journal of Thoracic Oncology</i> , 2006 , 1, 478-86	8.9	13
206	Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.. <i>Nature</i> , 2022 ,	50.4	13
205	Survival rates in T1 and T2 gastric cancer: A Western report. <i>Journal of Surgical Oncology</i> , 2016 , 114, 602-606	12	
204	Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients. <i>Carcinogenesis</i> , 2014 , 35, 2031-8	4.6	12
203	Phase II study of didemnin B in advanced colorectal cancer. <i>Investigational New Drugs</i> , 1992 , 10, 211-3	4.3	12
202	Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1990 , 26, 223-6	3.5	12
201	Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. <i>Oncotarget</i> , 2017 , 8, 28696-28710	3.3	12
200	Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. <i>Oncotarget</i> , 2017 , 8, 81430-81440	3.3	12
199	Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2021 , 124, 963-974	8.7	12
198	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. <i>Nature Communications</i> , 2021 , 12, 5606	17.4	12
197	Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 554-562	4	11
196	Surgical Resection First for Localized Gastric Adenocarcinoma: Are There Adjuvant Options?. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3085-91	2.2	11
195	Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma. <i>Molecular Oncology</i> , 2020 , 14, 1410-1426	7.9	11
194	Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018 , 32, 512	5.2	11

193	Repeat staging laparoscopy for gastric cancer after preoperative therapy. <i>Journal of Surgical Oncology</i> , 2018 , 118, 61-67	2.8	11
192	Anti-angiogenic agent ramucirumab: meaningful or marginal?. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 367-79	3.5	11
191	Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. <i>Cancer</i> , 2008 , 113, 1302-8	6.4	11
190	Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 64, 700-8	4	11
189	FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-Oncology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4137-TPS4137	2.2	11
188	Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, 104-11	7.1	11
187	Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. <i>British Journal of Cancer</i> , 2018 , 118, 52-61	8.7	11
186	Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2016 , 23, 1948-55	3.1	10
185	Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?. <i>British Journal of Cancer</i> , 2019 , 121, 278-280	8.7	10
184	Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. <i>Cancer</i> , 2010 , 116, 4487-94	6.4	10
183	Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. <i>Journal of Gastrointestinal Oncology</i> , 2016 , 7, 499-505	2.8	10
182	D-mannose: a novel prognostic biomarker for patients with esophageal adenocarcinoma. <i>Carcinogenesis</i> , 2017 , 38, 162-167	4.6	9
181	PPAR γ Interacts with the Hippo Coactivator YAP1 to Promote SOX9 Expression and Gastric Cancer Progression. <i>Molecular Cancer Research</i> , 2020 , 18, 390-402	6.6	9
180	Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018 , 156, 406-413.e3	1.5	9
179	101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. <i>Oncology</i> , 2017 , 93, 243-248	3.6	9
178	Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. <i>Diseases of the Colon and Rectum</i> , 2014 , 57, 941-57	3.1	9
177	Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion. <i>International Journal of Cancer</i> , 1986 , 38, 245-9	7.5	9
176	Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. <i>Gut</i> , 2021 , 70, 2055-2065	19.2	9

175	Linitis Plastica: a Distinct Type of Gastric Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2020 , 24, 1018-1025.	3.3	9
174	Evolution of gastric surgery techniques and outcomes. <i>Chinese Journal of Cancer</i> , 2016 , 35, 69		9
173	Adjuvant therapy for gastric carcinoma patients in the past 15 years	1999 , 86, 1657	9
172	Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. <i>Journal of Surgical Oncology</i> , 2019 , 120, 1350-1357	2.8	8
171	Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 , 162, 1404-1412.	12.15	8
170	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. <i>Journal of Oncology Practice</i> , 2017 , 13, 53-57	3.1	8
169	Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 167-72	4	8
168	Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux. <i>Annals of Thoracic Surgery</i> , 2005 , 79, 1716-23	2.7	8
167	A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. <i>Cancer Investigation</i> , 1990 , 8, 619-21	2.1	8
166	Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. <i>Annals of Surgery</i> , 2020 , 272, 311-318	7.8	8
165	Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. <i>Targeted Oncology</i> , 2018 , 13, 99-106	5	8
164	Translating genomic profiling to gastrointestinal cancer treatment. <i>Future Oncology</i> , 2017 , 13, 919-934	3.6	7
163	Early clinical esophageal adenocarcinoma (cT1): Utility of CT in regional nodal metastasis detection and can the clinical accuracy be improved?. <i>European Journal of Radiology</i> , 2017 , 88, 56-60	4.7	7
162	Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. <i>Oncology</i> , 2020 , 98, 289-294	3.6	7
161	Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma. <i>World Journal of Surgical Oncology</i> , 2020 , 18, 39	3.4	7
160	Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2018 , 22, 1325-1333	3.3	7
159	Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2018 , 117, 678-684	2.8	7
158	Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. <i>Oncology</i> , 2016 , 91, 55-60	3.6	7

157	Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 383-92	4.2	7
156	Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2017 , 24, 2291-2301	3.1	7
155	Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. <i>Oncology</i> , 2012 , 82, 347-51	3.6	7
154	Oral etoposide for patients with advanced adenocarcinoma of the pancreas. <i>Investigational New Drugs</i> , 1998 , 16, 333-5	4.3	7
153	Recent advances in treating oesophageal cancer. <i>F1000Research</i> , 2020 , 9,	3.6	7
152	A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. <i>DMM Disease Models and Mechanisms</i> , 2019 , 12,	4.1	7
151	A Phase II Trial of Cytorreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology. <i>Annals of Surgical Oncology</i> , 2021 , 28, 258-264	3.1	7
150	Potentially curable gastric adenocarcinoma treated without surgery. <i>European Journal of Cancer</i> , 2018 , 98, 23-29	7.5	7
149	Ushering in Liquid Biopsy for the Microsatellite Status: Advantages and Caveats. <i>Clinical Cancer Research</i> , 2019 , 25, 6887-6889	12.9	6
148	The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1439-1450	6.1	6
147	Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 1380-1387	3.3	6
146	An improved strategy for CRISPR/Cas9 gene knockout and subsequent wildtype and mutant gene rescue. <i>PLoS ONE</i> , 2020 , 15, e0228910	3.7	6
145	Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. <i>Lancet Oncology, The</i> , 2016 , 17, 1628-1629	21.7	6
144	Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique. <i>Journal of Gastrointestinal Surgery</i> , 2018 , 22, 2013-2019	3.3	6
143	Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919864850	5.4	6
142	Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2017 , 21, 1563-1570	3.3	6
141	Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma. <i>Cancer</i> , 1999 , 85, 2336-9	6.4	6
140	Colorectal ornithine decarboxylase activity in human mucosa and tumors: elevation of enzymatic activity in distal mucosa. <i>Journal of Surgical Oncology</i> , 1991 , 47, 117-20	2.8	6

139	Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 36, 104-111	7.1	6
138	Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. <i>Oncotarget</i> , 2019 , 10, 4703-4718	3.3	6
137	Recent Developments in Cytotoxic Therapy for Advanced Gastric or Gastroesophageal Carcinoma: The Phase III Trials. <i>Gastrointestinal Cancer Research: GCR</i> , 2007 , 1, S16-21		6
136	Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2020 , 110, 398-405	2.7	6
135	LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma. <i>Cancers</i> , 2020 , 12,	6.6	6
134	Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). <i>Journal of Clinical Oncology</i> , 2021 , 39, 990-1000	2.2	6
133	A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 173-9	7.3	6
132	Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2020 , 27, 534-542	3.1	6
131	Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. <i>British Journal of Cancer</i> , 2018 , 118, 331-337	8.7	6
130	Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). <i>European Journal of Cancer</i> , 2019 , 121, 130-143	7.5	5
129	Time-to-Treatment Failure As the Primary End Point of a First-Line Advanced Gastric Cancer Randomized Trial: How Confused Would You Want Us to Be?. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2410 ^{2.2}		5
128	Molecular biology and immunology of gastric cancer peritoneal metastasis. <i>Translational Gastroenterology and Hepatology</i> , 2020 , 5, 57	5.2	5
127	Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology. <i>Annals of Surgical Oncology</i> , 2020 , 27, 2806-2811	3.1	5
126	Mutation of the hMSH2 gene in two families with hereditary nonpolyposis colorectal cancer. <i>Human Mutation</i> , 1996 , 7, 327-33	4.7	5
125	Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma. <i>Cancer Investigation</i> , 1994 , 12, 488-90	2.1	5
124	A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. <i>Cancer</i> , 1993 , 72, 2560-3	6.4	5
123	Differential effects of parenteral nutrition on tumor growth and erythrocyte polyamine levels in the rat. <i>Journal of Parenteral and Enteral Nutrition</i> , 1989 , 13, 590-5	4.2	5
122	Polyamine-directed preferential nutritional repletion of normal tissues in tumor-bearing hosts. <i>International Journal of Cancer</i> , 1988 , 42, 744-7	7.5	5

121	Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. <i>Investigational New Drugs</i> , 1988 , 6, 47-50	4.3	5
120	Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. <i>Gut</i> , 2021 , 70, 2238-2248	19.2	5
119	Current therapeutic landscape for advanced gastroesophageal cancers. <i>Annals of Translational Medicine</i> , 2018 , 6, 78	3.2	5
118	Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. <i>Oncology</i> , 2019 , 96, 252-258	3.6	4
117	Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. <i>Gastric Cancer</i> , 2020 , 23, 904-912	7.6	4
116	A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 321-325	2.7	4
115	Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. <i>Medical Oncology</i> , 2017 , 34, 135	3.7	4
114	Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. <i>Oncology</i> , 2015 , 89, 305-10	3.6	4
113	Paraneoplastic neurological syndromes associated with gastric cancer: a case report and review of the literature. <i>Clinical Journal of Gastroenterology</i> , 2012 , 5, 355-60	1.1	4
112	Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. <i>Modern Pathology</i> , 2009 , 22, 1612-21	9.8	4
111	Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction. <i>Annals of Surgical Oncology</i> , 2007 , 14, 1305-1311	3.1	4
110	Phase II study of spirogermanium in patients with advanced colorectal carcinoma. <i>Investigational New Drugs</i> , 1986 , 4, 383-5	4.3	4
109	CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4132-TPS4132	2.2	4
108	Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. <i>Annals of Translational Medicine</i> , 2018 , 6, 80	3.2	4
107	Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection. <i>British Journal of Cancer</i> , 2020 , 123, 1244-1252	8.7	4
106	Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. <i>Annals of Surgery</i> , 2021 , 273, 751-757	7.8	4
105	College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2021 , 26, e780-e793	5.7	4
104	Cancer stem cells in esophageal cancer and response to therapy. <i>Cancer</i> , 2018 , 124, 3962-3964	6.4	4

103	Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. <i>Annals of Translational Medicine</i> , 2021 , 9, 1189	3.2	4
102	The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. <i>Gastric Cancer</i> , 2019 , 22, 1100-1108	7.6	3
101	Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
100	Palliative care for advanced gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 575-580	3.5	3
99	Cloning of ground-state intestinal stem cells from endoscopic biopsy samples. <i>Nature Protocols</i> , 2020 , 15, 1612-1627	18.8	3
98	Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. <i>Oncology</i> , 2016 , 90, 10-20	3.6	3
97	Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. <i>Oncology</i> , 2015 , 89, 65-9	3.6	3
96	Future developments in esophageal cancer research. <i>Gastroenterology Clinics of North America</i> , 2009 , 38, 183-8, x	4.4	3
95	Influence of total parenteral nutrition on tumor growth and polyamine biosynthesis of fibrosarcoma-bearing rats after induced cachexia. <i>Journal of Parenteral and Enteral Nutrition</i> , 1988 , 12, 441-4	4.2	3
94	Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. <i>American Journal of Cancer Research</i> , 2020 , 10, 3947-3972	4.4	3
93	Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2020 , 20, 313-327	3.2	3
92	IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. <i>Advances in Radiation Oncology</i> , 2020 , 5, 369-376	3.3	3
91	Laparoscopic HIPEC for Low-Volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020 , 27, 5047-5056	3.1	3
90	Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer. <i>Cancer Science</i> , 2020 , 111, 4205-4217	6.9	3
89	Proteomics approach to identify biomarkers for upper gastrointestinal cancer. <i>Expert Review of Proteomics</i> , 2016 , 13, 1041-1053	4.2	3
88	Benchmarks for nodal yield and ratio for node-positive gastric cancer. <i>Surgery</i> , 2021 , 170, 1231-1239	3.6	3
87	Current status of ramucirumab in gastroesophageal adenocarcinoma. <i>Future Oncology</i> , 2017 , 13, 1585-1592	3.2	2
86	Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2805-2806	2.2	2

85	Ramucirumab for the treatment of gastroesophageal cancers. <i>Expert Opinion on Orphan Drugs</i> , 2015 , 3, 737-746	1.1	2
84	Early versus Delayed Therapy of Advanced Gastric Cancer Patients--Does It Make a Difference?. <i>Oncology</i> , 2015 , 89, 215-20	3.6	2
83	Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells. <i>Surgery Today</i> , 2020 , 50, 1223-1231	3	2
82	Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. <i>Journal of Surgical Oncology</i> , 2020 , 122, 422-432	2.8	2
81	Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series. <i>Journal of Surgical Oncology</i> , 2019 , 120, 1137-1141	2.8	2
80	Is the addition of cisplatin to S-1 better than S-1 alone for patients with advanced gastroesophageal cancer?. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 508-9		2
79	Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1989 , 24, 41-4	3.5	2
78	Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. <i>Oncotarget</i> , 2017 , 8, 79356-79365	3.3	2
77	Recent trend in gastric cancer treatment in the USA. <i>Journal of Cancer Metastasis and Treatment</i> , 2018 , 4,	3.8	2
76	Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. <i>Annals of Gastroenterological Surgery</i> , 2020 , 4, 369-378	4.3	2
75	Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting deficiency. <i>Gut</i> , 2021 ,	19.2	2
74	Is targeted therapy possible for patients with gastric adenocarcinoma?. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2371-2374	4	2
73	Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. <i>Annals of Thoracic Surgery</i> , 2021 , 111, 1133-1140	2.7	2
72	Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer. <i>British Journal of Cancer</i> , 2021 , 124, 595-603	8.7	2
71	Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response. <i>Cancers</i> , 2021 , 13,	6.6	2
70	Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. <i>Oncology</i> , 2003 , 17, 20-2	1.8	2
69	Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. <i>Annals of Thoracic Surgery</i> , 2021 ,	2.7	2
68	Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101926	2.2	2

67	Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. <i>Oncology</i> , 2015 , 88, 332-6	3.6	1
66	Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. <i>Oncology</i> , 2020 , 98, 542-548	3.6	1
65	Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C and improved tolerability, in patients with solid tumors. <i>Investigational New Drugs</i> , 2020 , 38, 1763-1773	4.3	1
64	Factors Associated with Resection and Survival After Laparoscopic HIPEC for Peritoneal Gastric Cancer Metastasis. <i>Annals of Surgical Oncology</i> , 2020 , 27, 4963-4969	3.1	1
63	Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. <i>Medicine (United States)</i> , 2020 , 99, e19295	1.8	1
62	Customization of therapy for gastroesophageal adenocarcinoma patients. <i>Chronic Diseases and Translational Medicine</i> , 2018 , 4, 8-17	3.9	1
61	Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. <i>Oncology</i> , 2018 , 95, 81-90	3.6	1
60	Reply to D. Vordermark. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3065-3065	2.2	1
59	Peek before you treat? Is it a fantasy or reality?. <i>Journal of Oncology Practice</i> , 2011 , 7, 338-9	3.1	1
58	Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma. <i>Investigational New Drugs</i> , 1998 , 16, 175-7	4.3	1
57	Chemotherapy of Colorectal Cancer. <i>Current Treatment Options in Gastroenterology</i> , 1999 , 2, 38-48	2.5	1
56	Recent advances in preoperative management of esophageal adenocarcinoma. <i>F1000Research</i> , 2017 , 6, 501	3.6	1
55	Cell-of-Origin Analysis of Metastatic Gastric Cancer Uncovers the Origin of Inherent Intratumor Heterogeneity and a Fundamental Prognostic Signature		1
54	Influence of induction chemotherapy (IC) in trimodality-eligible esophageal cancer patients: Secondary analysis of a randomized trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4027-4027	2.2	1
53	Comparison of laparoscopy versus mini-laparotomy for jejunostomy placement in patients with gastric adenocarcinoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021 , 35, 6577-6582	5.2	1
52	Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer. <i>Journal of Surgical Oncology</i> , 2020 , 122, 1373-1382	2.8	1
51	Chemoradiotherapy followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: A Systematic Review and Individual Patient Data Meta-Analysis. <i>Annals of Surgery</i> , 2021 ,	7.8	1
50	Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. <i>Annals of Surgery</i> , 2021 , 274, 544-548	7.8	1

49	Potentially Curable Cancers of the Esophagus and Stomach. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 1307-18	6.4	1
48	Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3786-3791	3.1	1
47	A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 9-10	19.4	1
46	Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2021 , 28, 758-765	3.1	1
45	Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. <i>Oncologist</i> , 2021 , 26, e414-e424	5.7	1
44	Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 665-679	9.7	1
43	Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. <i>Journal of Surgical Oncology</i> , 2021 , 123, 911-922	2.8	1
42	Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy. <i>Oncology</i> , 2021 , 99, 659-664	3.6	1
41	Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency. <i>Journal of Surgical Oncology</i> , 2018 , 117, 707-709	2.8	1
40	Oesophageal preservation in locally advanced oesophageal cancer. <i>Lancet Oncology, The</i> , 2018 , 19, e43021.7	1.7	1
39	Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. <i>Japanese Journal of Cancer and Chemotherapy</i> , 2006 , 33 Suppl 1, 117-20	0.2	1
38	Genome-wide host methylation profiling of anal and cervical carcinoma. <i>PLoS ONE</i> , 2021 , 16, e0260857	3.7	1
37	Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer.. <i>Gastric Cancer</i> , 2022 , 25, 542	7.6	1
36	Rare Esophageal Leptomeningeal Metastases Detected on 18F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2020 , 45, 334-335	1.7	0
35	Genomic profiling of colorectal cancers and the future of personalized treatment. <i>Colorectal Cancer</i> , 2017 , 6, 11-22	0.8	0
34	A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and stage IV peritoneal disease.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 361-361	2.2	0
33	Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives.. <i>World Journal of Gastrointestinal Oncology</i> , 2022 , 14, 181-202	3.4	0
32	Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 207	12.8	0

31	Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis. <i>European Journal of Cancer</i> , 2022 , 170, 119-130	7.5	0
30	Advances in therapeutic options for esophageal and esophagogastric junctional adenocarcinoma. <i>Expert Opinion on Orphan Drugs</i> , 2017 , 5, 549-557	1.1	
29	Predictive Biomarkers for Therapy in Adenocarcinoma of the Upper Digestive Tract 2017 , 118-129		
28	Ramucirumab for the treatment of gastric adenocarcinoma. <i>Expert Opinion on Orphan Drugs</i> , 2018 , 6, 449-455	1.1	
27	Reply. <i>Gastroenterology</i> , 2018 , 155, 934-935	13.3	
26	Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. <i>Oncology</i> , 2018 , 94, 345-353	3.6	
25	After local therapy for esophageal cancer, should we continue to survey patients and, if so, why and how?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 2-3	7.3	
24	Anal canal cancer: biology and therapy. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 137-146	1.1	
23	Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma. Reply to R. Gertler et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2112-3	2.2	
22	The Biology of K-Ras and B-Raf Mutations in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2010 , 6, 206-211	1	
21	Are capecitabine and oxaliplatin as effective as fluorouracil and cisplatin for gastroesophageal cancer?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008 , 5, 414-5		
20	Status of Newer Chemotherapeutic Strategies for the Treatment of Metastatic Gastric Cancer. <i>American Journal of Cancer</i> , 2005 , 4, 65-70		
19	Editorial commentary: Introduction to the first issue. <i>Current Colorectal Cancer Reports</i> , 2005 , 1, 1-1	1	
18	Why should localized gastric adenocarcinoma patients fare poorly after adjunctive therapy compared to surgery alone?. <i>Chinese Clinical Oncology</i> , 2021 , 10, 32	2.3	
17	Pharmaceutical advances in the treatment of gastric adenocarcinoma.. <i>Expert Opinion on Pharmacotherapy</i> , 2022 , 1-11	4	
16	Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 279-279	2.2	
15	Localized Gastroesophageal Cancers: Can We Shift the Current Treatment Paradigms?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022 , 20, 100-101	7.3	
14	Preoperative therapy for potentially resectable localized gastric cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009 , 3, 36-7		

- 13 Accomplishments in 2007 in the management of advanced gastroesophageal cancer. *Gastrointestinal Cancer Research: GCR*, **2008**, 2, S47-50
- 12 Accomplishments in gastrointestinal oncology in 2008: conclusion. *Gastrointestinal Cancer Research: GCR*, **2009**, 3, S79
- 11 GCR Graduates From Nursery School on a Fast Track to Editorial Excellence. *Gastrointestinal Cancer Research: GCR*, **2011**, 4, 39
- 10 The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancer. *Annals of Translational Medicine*, **2016**, 4, 38 3.2
- 9 Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance. *Oncoscience*, **2018**, 5, 214-215 0.8
- 8 Trastuzumab + fluoropyrimidine maintenance in the frontline setting for non-progressing advanced HER-2 positive gastroesophageal adenocarcinoma.. *Journal of Clinical Oncology*, **2020**, 38, 291-291 2.2
- 7 Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification. *Oncology*, **2020**, 98, 884-888 3.6
- 6 Determinants of Survival for Patients with Neoadjuvant-Treated Node-Negative Gastric Cancer. *Annals of Surgical Oncology*, **2021**, 28, 6638-6648 3.1
- 5 Long non-coding RNAs are significantly associated with prognosis and response to therapies in gastric cancer. *Clinical and Translational Medicine*, **2021**, 11, e421 5.7
- 4 The role of ramucirumab and pembrolizumab combination in patients with advanced non-small cell lung cancer, gastroesophageal adenocarcinoma, or urothelial carcinoma. *Chinese Clinical Oncology*, **2021**, 10, 30 2.3
- 3 Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction. *Oncology*, **2003**, 17, 10-2 1.8
- 2 Proteomic profiling of key signatures from gastric lesions to early gastric cancer.. *EBioMedicine*, **2021**, 74, 103744 8.8
- 1 Esophageal Adenocarcinoma31-113